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We are grateful to Dr Catalana-
Lopez for his continued comments
regarding our work.
Although we do not want to prolong
unnecessarily this correspondence, a
couple of points are worthy of note
in his response.
First, the suggestion of including
observational evidence in the meta-
analysis is flawed, and we found our-
selves in this position. As Rosenbaum
and Rubin,1 the propensity score
methods used by the authors can
only address confounding when case
mix adjustment is possible to the
extent that the prescriber’s decision
to prescribe a treatment is otherwise
ignorable. This is clearly not the
case in our situation, in which the732 The Journal of Thoracic and Cobservational studies describe a sub-
stantial latency (unmeasurable bias)
associated with the decision to pre-
scribe, which has been incorrectly in-
terpreted as a risk associated with
aprotonin.2,3 Thus, following Dr
Catalana-Lopez’s advice in this
situation would actually compound
the previous errors of interpretation
that have led us to our difficulties
with this agent.
Second, Dr Catalana-Lopez is sim-
ply incorrect when he suggests that
network meta-analyses have the
same status as observational studies.
Network meta-analyses preserve the
original randomization in trials, and
provide fully conditional estimates of
treatment effect. However, network
meta-analyses require an additional
assumption (of exchangeability; ie,
that subjects share characteristics
from the overall population and may,
thus, appear in any of the trials).
Thus, rather than fully giving up the
protection of randomization, we may
consider network meta-analyses to
be quasi-randomized estimates.
Finally, with regard to potential
conflicts of interest, they should be
declared upfront and leave the reader
to decide of their importance. These
authors take conflicts of interest seri-
ously and, as indicated by Dr
Catalana-Lopez, have declared all
possible conflicts in accordance with
required journal requirements.
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CONTRIBUTE TO THE QUASI
PRESERVATION OF
CARDIOPROTECTION BY
REMOTE PRECONDITIONING
WITH ISOFLURANE BUT NOT
PROPOFOL IN CABG
To the Editor:
We read with great interest the
article by Kottenberg and colleagues1
published online in The Journal of
Thoracic and Cardiovascular Surgery
onMarch 1, 2013. They have done a se-
ries of impressive translational works to
explore the underlying mechanisms of
cardioprotection by remote ischemic
preconditioning (RIPC) with isoflurane
or propofol in patients undergoing coro-
nary artery bypass grafting (CABG).1-3
In their fundamental study published in
Acta Anaesthesiologica Scandinavica,2
they designed 2 independent substudies
and found that isoflurane may be
more effective in the preservation of
cardioprotection by RIPC than
propofol. Then, based on 2 conse-
quently separated and independent
studies,2,3 they believed that differen-
tial activation of signal transducer
and activator of transcription 5
(STAT 5) phosphorylation may be the
contributing factor.
Nevertheless, there remains incon-
clusive information about this inter-
esting issue when looking into the
fundamental study. In that study,2 the
male proportion may be even within
the substudy (RIPC vs control with
isoflurane; RIPC vs control with pro-
pofol); however, it may be uneven be-
tween the 2 substudies (isoflurane vs
propofol, 89.7% vs 75.8%; mean dif-
ference, 14%).
Accumulating evidence from ani-
mal studies has supported gender-
specific cardioprotection by ischemic3
FIGURE 1. Meta-regression plot of male proportion (%) on standardized mean difference (SMD)
of myocardial enzyme levels (coefficient, –0.022; P ¼ .098). The area of each circle is inversely
proportional to the variance of the SMD. Data taken from Zhou and colleagues.5
Letters to the Editorconditioning.4 Moreover, our recent
study,5 including 10 randomized trials
using the meta-regression method
found an increased effect size (stan-
dardized mean difference) in postin-
tervention myocardial enzyme levels
of ischemic postconditioning by 0.22
per 10% increase in male proportion
(Figure 1), indicating that a study
with more male patients may result in
a more pronounced effect than a study
with fewer male patients. Hence, in
their fundamental study, the authors
cannot exclude the potential role of
gender disparity in the quasi preserva-
tion of cardioprotection by RIPC with
isoflurane, but not propofol, in CABG.
At least, as the authors stated in the
limitation section, both positive and
negative controls are essential in one
study, especially for the exploration
of the role of STAT 5. The cardiopro-
tective difference between isoflurane
and propofol in the setting of RIPC
needs further more rigorous studies.
Chenghui Zhou, MD
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We thank Zhou and colleagues for
their comments and interest in our
recent work.1,2 We appreciate that
they considered us to have done
a series of impressive translational
studies to explore the mechanisms of
cardioprotection by remote ischemic
preconditioning (RIPC) with isofluraneof Thoracic and Cardiovascular Surgeor propofol in patients undergoing
coronary artery bypass grafting
(CABG) surgery.1-3
Zhou and colleagues speculate that
there might be an unrecognised effect
of gender on the protection provided
by RIPC and, thus, on our results.
They underline this speculation by a
meta-analysis including 10 random-
ized trials. However, these data are
derived from studies related to
ischemic postconditioning,4 rather
than RIPC, and these 2 phenomena
may be mechanistically different.5
In our studies, in contrast to others
that have not addressed the impact of
anesthetics,6 we showed that propofol
interferes with the protection by
RIPC, whereas the volatile anesthetic
isoflurane2 does not. Furthermore,
the activation of signal transducer
and activator of transcription 5 phos-
phorylation may be part of the mecha-
nism by which RIPC exerts its
cardioprotection during isoflurane
anesthesia.1,3 Indeed, the gender
distribution in our studies was not
comparable in all subgroups.1,2
Certainly, therefore, effects provided
by RIPC may be modified by gender,
but this has not been studied. We
agree that it would be worthwhile to
examine whether there is a gender-
specific effect of cardioprotection not
only by ischemic postconditioning but
also by RIPC. However, our studies
were neither designed nor powered to
examine a potential role of gender
disparity. Therefore, we can neither
exclude nor confirm gender effects on
cardioprotection provided by RIPC.
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